| Literature DB >> 14769383 |
Laurent Magy1, Caroline Mertens, Virginia Avellana-Adalid, Mahamane Keita, François Lachapelle, Brahim Nait-Oumesmar, Bertrand Fontaine, Anne Baron-Van Evercooren.
Abstract
Transplantation of glial cells into the central nervous system (CNS) may be a promising approach for the treatment of myelin disorders such as multiple sclerosis (MS). Myelination by transplantation of oligodendrocyte precursors has been obtained in different animal models of demyelination. A strategy to favor CNS remyelination is to enrich the lesioned areas in growth factors to stimulate the quiescent population of oligodendrocyte precursors. In this context, we have developed a genetically modified CG4 cell line (CG4-FGF2), which are able to release significant amounts of fibroblast growth factor 2 (FGF2) in a controlable fashion in vitro. The data presented here demonstrate that upon induction with Dox, CG4-FGF2 cells retain their capacity to differentiate in vitro. Additionally, we provide evidence that FGF2 release by engineered cells enhance proliferation and migration of cells of the oligodendrocyte lineage without preventing them to differentiate and myelinate axons in vitro.Entities:
Mesh:
Substances:
Year: 2003 PMID: 14769383 DOI: 10.1016/j.expneurol.2003.08.019
Source DB: PubMed Journal: Exp Neurol ISSN: 0014-4886 Impact factor: 5.330